

Referências Bibliográficas

Capítulo 1 – Hipertensão Arterial:

A Importância do Problema

1. Mansur AP, Favarato D, Sousa MFM et al. Tendência do risco de morte por doenças circulatórias no Brasil de 1979 a 1996. *Arq Bras Cardiol*, 2001; 76(6): 497–503.
2. Sousa MFM, Timmerman A, Serrano Jr. CV et al. Tendências do risco de morte por doenças circulatórias nas cinco regiões do Brasil no período de 1979 a 1996. *Arq Bras Cardiol*, 2001; 77(6): 562–8.
3. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Chapter #1 pag 3 – NIH Publication # 98-4080 november 1997.
4. Freitas OC, Resende CF, Marques NJ et al. Prevalence of hypertension in the urban population of Catanduva, in the State of Sao Paulo, Brazil. *Arq Bras Cardiol*, 2001; 77(1): 9–21.
5. Fuchs FD, Moreira LB, Moraes RS et al. Prevalência de hipertensão arterial sistêmica e fatores associados na região urbana de Porto Alegre: estudo de base populacional. *Arq Bras Cardiol*, 1995; 63: 473–9.
6. Lolio CA. Prevalência de hipertensão arterial em Araraquara. *Arq Bras Cardiol*, 1990; 55: 167–73.
7. Martins IS, Marucci MF, Velasquez-Melendez G et al. Doenças cardiovasculares ateroscleróticas, dislipidemias, hipertensão, obesidade e diabetes melito em população da área metropolitana da região Sudeste do Brasil. III – Hipertensão. *Rev Saúde Pública*, 1997; 31(5): 466–71.
8. Rego RA, Berardo FA, Rodrigues SS et al. Risk factors for chronic non-communicable diseases: a domiciliary survey in the municipality of Sao Paulo, SP (Brazil). *Methodology and preliminary results. Rev Saúde Pública*, 1990; 24(4): 277–85.
9. Ayres JE. Prevalence of hypertension in the city of Piracicaba. *Arq Bras Cardiol*, 1991; 57: 33–6.
10. Lessa I. Epidemiologia da hipertensão arterial sistêmica e da insuficiência cardíaca no Brasil. *Rev Bras Hipertens*, 2001; 8: 383–92.
3. Perloff D, Grim C, Flack J, Frohlich ED et al. Human blood pressure determination by sphygmomanometry. *Circulation*, 1993; 88: 2460–70.
4. Petrie JC, O'Brien ET, Littler WA et al. Recommendations on blood pressure measurement. *Br Med J*, 1986; 293: 611–5.
5. O'Brien E. Will mercury manometers soon be obsolete? *J Human Hypertens*, 1995; 9: 933–34.
6. Bailey RH, Knaus VL, Bauer JH. Aneroid sphygmomanometers: an assessment of accuracy at a University Hospital and Clinics. *Arch Intern Med*, 1991; 151: 1409–12.
7. Knight T, Leech F, Jones A et al. Sphygmomanometers in use in general practice: an overlooked aspect of quality in patient care. *J Human Hypertens*, 2001; 15: 681–4.
8. O'Brien E et al. Blood pressure measuring devices: recommendations of the European Society of Hypertension. *BMJ*, 2001; 322: 531–6.
9. Verdecchia P, Schillaci G, Borgioni C et al. White coat hypertension and white coat effect: similarities and differences. *Am J Hypertens*, 1995; 8: 790–8.
10. Palatini P. Exercise hemodynamics in the normotensive and the hypertensive subject. *Clin Sci*, 1994; 87: 275–87.
11. Rummel RM, Crawford M, Bruce P. The physiological effects of inhaling exhaled cigarette smoke in relation to attitude of the nonsmoker. *J School Health*, 1975; 45: 524–8.
12. Potter JF, Watson RD, Skan W et al. The pressor and metabolic effects of alcohol in normotensive subjects. *Hypertension*, 1986; 8: 625–31.
13. Van Dusseldorp, Smits P, Lenders JWM et al. Boiled coffee and blood pressure. A 14-week controlled trial. *Hypertension*, 1991; 18: 607–13.
14. Scriven AJ, Brown MJ, Murphy MB et al. Changes in blood pressure and plasma catecholamines caused by tyramine and cold exposure. *J Cardiovasc Pharmacol*, 1984; 6: 954–60.
15. Foster-Fitzpatrick L, Ortiz A, Sibilano H et al. The effects of crossed leg on blood pressure measurement. *Nurs Res*, 1999; 48: 105–8.
16. Peters GL, Binder SK, Campbell NR. The effect of crossing legs on blood pressure: a randomized single blind crossover study. *Blood Press Monit*, 1999; 4: 97–101.
17. Palatini P. Exercise hemodynamics in the normotensive and the hypertensive subject. *Clin Sci*, 1994; 87: 275–87.
18. Russel AE, Wing LM, Smith SA et al. Optimal size of cuff bladder for indirect measurement of arterial pressure in adults. *J Hypertens*, 1989; 7: 607–13.

Capítulo 2 – Diagnóstico & Classificação

1. McKay DW, Campbell NR, Parob LS et al. Clinical assessment of blood pressure. *J Hum Hypertens* 1990; 4: 639–45.
2. McAlister FA, Straus SE. Measurement of blood pressure: an evidence based review. *BMJ* 2001; 322: 908–11.

19. Terent A, Breig-Asberg E. Epidemiological perspective of body position and arm level in blood pressure measurement. *Blood Press*, 1994; 3: 156–63.
 20. Wen SW, Kramer MS, Hoey J et al. Terminal digit preference, random error, and bias in routine clinical measurement of blood pressure. *J Clin Epidemiol*, 1993; 46: 1187–93.
 21. Rosner B, Polk F. Predictive values of routine blood pressure measurements in screening for hypertension. *Am J Epidemiol*, 1983; 117: 429–42.
 22. Perry HM, Miller JP. Difficulties in diagnosing hypertension: implications and alternatives. *J Hypertens*, 1992; 10: 887–96.
 23. Brueren MM, Petri H, van Weel C et al. How many measurements are necessary in diagnosing mild to moderate hypertension. *Fam Pract*, 1997; 14: 130–5.
 24. III Diretrizes para o Uso da Monitorização Ambulatorial da Pressão Arterial. I Diretrizes para o Uso da Monitorização Residencial da Pressão Arterial. *Rev Bras Hipertens*, 2001; 8: 143–55.
 25. Padfield PL, Lindsay BA, Mc Laren JA et al. Changing relation between home and clinic blood pressure measurements: do home measurements predict clinic hypertension? *Lancet*, 1997; ii: 322–4.
 26. Bortoloto LA, Henry O, Hanon O et al. Validation of two devices for self-measurement of blood pressure by elderly patients according to the revised British Hypertension Society protocol: the Omron HEM-722C and HEM-735C. *Blood Press Monit*, 1999; 4: 21–5.
 27. Friedman RH, Kazis LE, Jette A et al. A tele communications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. *Am J Hypertens*, 1996; 9: 285–92.
 28. Imai Y, Poncelet P, DeBuyzere M et al. Prognostic significance of self-measurements of blood pressure. *Blood Press Monit*, 2000; 5: 137–43.
 29. Yarows S. Home blood pressure monitoring in primary care. *Blood Pressure Monitoring* 1998; 3: S11–S17.
 30. Pickering TG, Krakoff L et al. American Society of Hypertension Expert Panel: conclusions and recommendations on the clinical use of home (self) and ambulatory blood pressure monitoring. *Am J Hypertens*, 1996; 9: 1–11.
 31. Vaur L, Dubroca I, Dutry-Aupagne C et al. Superiority of home blood pressure measurements over office measurements for testing antihypertensive drugs. *Blood Press Monit*, 1998; 3: 107–14.
 32. Soghikian K, Casper SM, Fireman BH et al. Home blood pressure in management of hypertension. *Can Med Assoc J*, 1978; 119: 1034–9.
 33. Staessen JÁ, O'Brien ET, Thijs L et al. Modern approaches to blood pressure measurements. *Occup Environ Med*, 2000; 57: 510–20.
 34. Thijs L, Staessen JÁ, Celis H et al. Reference values for self-recorded blood pressure. A meta-analysis of summary data. *Arch Intern Med*, 1998; 158: 481–8.
 35. Fagard R, Staessen J, Thijs L et al. Multiple standardized clinic blood pressure may predict left ventricular mass as well as ambulatory monitoring. *Am J Hypertens*, 1995; 8: 533–40.
 36. O'Brien E, Coats A, Owens P et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. *BMJ*, 2000; 320: 1128–34.
 37. Update on the 1987 Task Force Report on high blood pressure in children and adolescents. A working group report from National high blood pressure education program. *Pediatrics*, 1996; 98: 649–58.
 38. Sgambatti MS, Pierin A, Mion Jr D. A medida da pressão arterial no idoso. *Rev Bras Hipertens*, 2000; 7: 65–70.
 39. Junqueira SM. Medida da pressão arterial na gestante. *Rev Bras Hipertens*, 2000; 7: 59–64.
 40. Cavallini MC, Roman MJ, Pickering TG et al. Is white coat hypertension associated with arterial disease or left ventricular hypertrophy? *Hypertension*, 1995; 26: 413–9.
 41. Julius S, Mejia A, Jones K et al. "White coat" versus "sustained" borderline hypertension in Tecumseh, Michigan. *Hypertension*, 1990; 16: 617–23.
 42. World Health Organization. International Society of Hypertension Guidelines for the Management of Hypertension 1999. *J Hypertens*, 1999; 17: 151–83.
- Capítulo 3 – Investigação Clínico-Laboratorial & Decisão Terapêutica**
1. Vagaonescu T, Phillips RA. Initial routine tests for diagnosis and risk stratification of the patient with hypertension. In: Weber M. *Hypertension Medicine*, New Jersey, Humana Press Inc, 2001, pp. 147–55.
 2. Zarnke KB, Levine M, McAlister FA et al. The 2000 Canadian recommendations for the management of hypertension: part two – Diagnosis and assessment of people with high blood pressure. *Can J Cardiol*, 2001; 17(12): 1249–63.
 3. Mansur AP, Favarato D, Sousa MFM et al. Tendência do risco de morte por doenças circulatórias no Brasil de 1979 – 1996. *Arq Bras Cardiol*, 2001; 76(6): 497–503.
- Capítulo 4 – Abordagem Multiprofissional**
1. Boulware E, Daumit GL, Frick KD, Minkovitz CS, Lawrence RS, Powe NR. An Evidence-Based Review of Patient-Centered Behavioral Interventions for Hypertension, *Am J Prev Med* 2001; 21(3): 221–32.

2. Júnior AJC, Labbadia EM. Hipertensão arterial e atendimento multiprofissional. Sociedade Brasileira de Clínica Médica – Regional São Paulo (matéria do site http://www.brasilmedicina.com/especial/clinicam_t1s1.asp).
3. Jardim PCV, Sousa ALL, Monego ET. Atendimento multiprofissional ao paciente hipertenso. *Rev Medicina Ribeirão Preto*, 1996; 29(2/3): 232–8.
4. Giorgi DMA. Estratégias especiais para melhoria da adesão/Equipes multiprofissionais e o papel da pré e da pós-consultas, Adesão ao tratamento: o grande desafio da hipertensão, Nobre F, Pierin A, Mion Jr D. São Paulo: Lemos Editorial, pg 71, 2001.
5. Black HR. *Studies Justifying the Use of Treatment to Prevent Cardiovascular Events*, Hypertension Medicine, Weber MA. Humana Press Inc., Totowa, NJ, 3–19, 2001.
6. Kreuter MW, Bull FC, Clark EM, Oswald DL. Understanding How People Process Health Information: A Comparison of Tailored and Nontailored Weight-Loss Materials. *Health Psychology*, 1999; 18(5): 487–94.
7. World Health Organization – International Society of Hypertension Guidelines for the Management of Hypertension, *J Hypertens*, 1999; 17: 151–83.
8. Lipp M, Rocha JC. *Stress, Hipertensão Arterial e Qualidade de Vida*. Campinas: Papirus, 1996 (2nd. ed.).
9. Lipp MN, Anderson DE. Cardiovascular Reactivity to Simulated Social Stress. *Stress Medicine*, 15: 249–57.
10. Lipp MN, Alcino AB, Bignotto MM, Malagris LN. O treino de controle de stress para hipertensos. *Estudos de Psicologia*, 1998; 15(3): 59–66.
11. Marcus BH, Dubbert PM, Forsyth L, McKenzie TL, Dunn A, Blair SN. Physical Activity Behavior Change: Issues in Adoption and Maintenance. *Health Psychology*, 2000; 19(1): 32–41.
12. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure (JNC VI), *Arch Intern Med*, 1997; 157: 2413–46.
13. Mion Jr D, Machado CA, Associações de pacientes e ligas de hipertensão, Adesão ao tratamento: o grande desafio da hipertensão, Nobre F, Pierin A, Mion Jr D. São Paulo: Lemos Editorial, pg 85, 2001.
14. Feldman EB. Role of nutrition in primary care. *Nutrition*, 2000; 16(7–8): 649–51.
15. Labrunie MCL, Mattos MSR, Braga JCF, Labrunie A. Controle dietoterápico ambulatorial. *Rev Soc Cardiol Estado de São Paulo*, 1997; 7(4): 465–74.
16. Thomas JA. Drug – nutrient interaction. *Nutr Rev*, 1995; 53(10): 271–82.
17. Rocha JC, Manigot DA, Moreira Filho DJ, Terra SRA. Avaliação do controle da hipertensão leve e moderada por profissionais de saúde não médicos. *Rev Bras Med (Cardiologia)* 1985; 4(2): 91–8.
18. Erikson SR, Slaughter R, Halapy H. Pharmacists' Ability to Influence Outcomes of Hypertension Therapy *Pharmacotherapy*, 1997; 7(1): 140–7.
19. Gleichmann UM, Philippi HH, Gleichmann SI, Laun R, Mellwing KP, Frohnapfel F, Liebermann A. Group Exercise Improves Patients Compliance in Mild to Moderate Hypertension. *J Hypertens*, 1989; 7(suppl.3): S77–80.
20. Gleichmann SI, Gleichmann UM, Mannebach HJ, Mellwing KP, Philippi HH. Educating Nurses in Blood Pressure Measurement and Hypertension Control. *J Hypertens*, 1989; 7(suppl. 3): S99–S102.
21. Grueninger UJ. Arterial hypertension: lessons from patient education. *Patient Education and Counseling*, 1995; 26: 37–55.
22. Grueninger UJ, Goldstein MG, Duffy FD. Patient Education in Hypertension: five essential steps. *J Hypertens*, 1989; 7(suppl. 3): S93–S98.
23. Jardim PCBV. Educação em saúde e controle da pressão arterial: atividades educativas em grupo: uma proposta de ação. São Paulo, 1998. 99p. Tese (doutorado). Fac. de Medicina da Universidade de São Paulo.
24. Hill MN. Strategies for patient education. *Clin Exp Hypertens*, 1989; 11: 1187–201.
25. Miller NH, Hill M, Kottke T, Ockene IS. The Multilevel Compliance Challenge: Recommendations for a Call to Action. A Statment for Healthcare Professionals. *Circulation*, 1997; 95: 1085–90.
26. Mullen P, Green L, Persinger G. Meta-analysis of patient education: a comparative analysis of intervention types. *Prev Med*, 1985; 14: 753–81.
27. Selby JV. Case Control Evaluations of Treatment and Program Efficacy. *Epidemiologic Reviews*, 1994; 16(1): 90–108.
28. Sousa ALL, Jardim PCBV. A Enfermagem e o Paciente Hipertenso em uma Abordagem Multiprofissional. *Rev Latino-Americana de Enfermagem*, Rib. Preto, 1994; 2: 5–7.
29. Westphal MF, Bogus CM, Faria MM. Grupos Focais: Experiências Precursoras em Programas Educativos em Saúde no Brasil. *Bol Sanit Panam*, 1996; 120(6): 472–81.

Capítulo 5 – Tratamento Não-Medicamentoso

1. Fung TT, Rimm EB, Spiegelman NR et al. Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. *Am J Clin Nutr*, 2001; 73: 61–7.
2. Issa JS, Francisco YA. Obesidade e doenças cardíacas: aspectos epidemiológicos e preventivos. *Rev Socesp, São Paulo*, 1996; 6(5): 558–63.
3. Millen BE, Fada PA, Quatromoni MS et al. Validation of a dietary pattern approach for evaluating nutritional risk: the Framingham Nutrition Studies. *Jr Am Diet Assoc*, 2001; 101: 187–94.

4. World Health Organization. Obesity. Preventing and managing the global epidemic. WHO/NUT/NCD 98.1. Geneva, jun 1997.
5. Kotchen TA, Mccarron DA. AHA Science Advisory. Dietary Electrolytes and Blood Pressure. A Statement for Healthcare Professionals From the American Heart Association Nutrition Committee. *Circulation*, 1998; 98: 613–7.
6. Jacques PF, Tucker KL. Are dietary patterns useful for understanding the role of diet in chronic disease? *Am J Clin Nutr*, 2001; 73: 1–2.
7. Fung TT, Willett WC, Stampfer MJ et al. Dietary patterns and the risk of coronary heart disease in women. *Arch Intern Med*, 2001; 161: 1857–62.
8. Kris-Etherton P, Eckel RH, Howard BV, Jeor SS et al. Lyon Diet Heart Study. Benefits of a Mediterranean-Style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease. *Circulation*, 2001; 103: 1823–5.
9. National Institutes of Health. National Heart Lung and Blood Institute. The DASH Diet. NIH publication 99–4062, 1999.
10. Deckelbaum RJ, Fisher EA, Winston M, Kumanyika S, Lauer RM, Pi-Sunyer FX et al. AHA Conference Proceedings. Summary of a Scientific Conference on Preventive Nutrition: Pediatric to Geriatrics. *Circulation*, 1999; 100: 450–6.
11. Monego ET. Alimentação e doenças cardiovasculares IN PORTO, CC (org) Doenças do Coração. Prevenção e Tratamento. Rio de Janeiro: Guanabara Koogan, 1998. p. 112–18.
12. MacMahon S. Alcohol consumption and hypertension. *Hypertension*, 1987; 9: 11–121.
13. Klatsky AL, Armstrong MA, Friedman GD. Risk of cardiovascular mortality in alcohol drinkers, ex-drinkers and nondrinkers. *Am J Cardiol*, 1990; 66: 1237–42.
14. Puddey IB, Beilin LJ, Vandongen R et al. Evidence for a direct effect of alcohol consumption on blood pressure in normotensive men: a randomized controlled trial. *Hypertension*, 1985; 7: 707–13.
15. Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects: a randomized controlled trial. *Lancet*, 1987; 1: 647–51.
16. Krauss RM, Eckel RH; Howard BH et al. AHA Dietary Guidelines. Revision 2000: A Statement for Healthcare Professionals From the Nutrition Committee of the American Heart Association. *Stroke*, 2000; 31: 2751–66.
17. Raw M, McNeill A, West R. Smoking cessation: evidence based recommendations for the healthcare system. *BMJ*, 1999; 318: 182–5.
18. Milkelsen KL, Winberg N, Hoegholm A et al. Smoking related to 24-h ambulatory blood pressure and heart rate. *Am J Hypertens*, 1997; 10: 483–94.
19. Mann SJ, James GD, Wang RS, Pickering TG. Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case-control study. *JAMA*, 1991; 265: 2226–8.
20. Verdecchia P, Schillaci G, Borgioni C et al. Cigarette smoking, ambulatory blood pressure and cardiac hypertrophy in essential hypertension. *J Hypertens*, 1995; 13: 1209–15.
21. Kaplan NM. Evidence in favor of moderate dietary sodium reduction. *Am J Hypertens*, 2000; 13: 8–13.
22. Rose G. Preventive cardiology: what lies ahead? *Preventive Med*, 1990; 19: 97–104.
23. Denton D. Can hypertension be prevented? *J Human Hypertens*, 1997; 11: 563–9.
24. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. *BMJ*, 1988; 297: 319–28.
25. Page LB, Vandeventer DE, Nader K et al. Blood pressure of Qash qai pastoral nomads in Iran in relation to culture, diet and body form. *Am J Clin Nutr*, 1981; 34: 527–38.
26. Poulter N, Khaw KT, Hopwood BEC et al. The Kenyan Luo migration study: observation in the initiation of a rise in blood pressure. *BMJ*, 1990; 300: 967–72.
27. Graudal NA, Galloe AM, Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. *JAMA*, 1998; 279: 1383–91.
28. Whelton PK, Appel LJ, Espeland MA et al. Sodium reduction and weight loss in the treatment of hypertension in older people: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. *JAMA*, 1998; 279: 839–46.
29. Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. *JAMA*, 1996; 275: 1590–7.
30. Elliott P. Observational studies of salt and blood pressure. *Hypertension*, 1991; 17(suppl 1): 13–8.
31. Law MR, Frost CD, Wald NJ. By how does dietary salt reduction lower blood pressure? I. Analysis of observational data among populations. *BMJ*, 1991; 302: 811–5.
32. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. *Am J Clin Nutr*, 1997; 65(suppl): 643S–651S.
33. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, Klag MJ. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. *J Am Med Assoc* 1997; 277(20): 1624–32.
34. Griffith LE, Guyatt GH, Cook RJ, Bucher HC, Cook DJ. The influence of dietary and nondietary calcium supplementation on blood pressure – an updated meta-analysis of randomized trials. *Am J Hypertens*, 1999; 12: 84–92.

35. Allender PS, Cutler JÁ, Follmann D, Cappuccio FP, Pryer J, Elliot P. Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials. *Ann Intern Med*, 1996; 124(9): 825–31.
36. McAlister FA, Levine N, Zarnke KB et al. The 2000 Canadian recommendations for the management of hypertension: Part one – therapy. *Can J Cardiol*, 2001; 17(5): 543–59.
37. Appel LJ, Moore TJ, Obarzanek E et al. DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. *N Engl J Med*, 1997; 336: 1117–24
38. Moore TJ, Vollmer WM, Appel LJ et al. Effect of dietary patterns on ambulatory blood pressure. Results from the Dietary Approaches to Stop Hypertension (DASH) Trial. *Hypertension*, 1999; 34: 472–77.
39. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. *Am J Epidemiol*, 1990; 132(4): 612–28.
40. Paffenbarger RS. Review: Contributions of epidemiology to exercise science and cardiovascular health. *Med Sci Sports Exerc*, 1988; 20(5): 426–38.
9. Hansson L, Lindholm, Niskanen L et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality on hypertension: the Captopril Prevention Project (CAPPP) randomized trial. *Lancet*, 1999; 353: 611–6.
10. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. *N Engl J Med*, 2000; 342: 145–53.
11. PROGRESS Collaborative Group. Randomized Trial of a perindopril-based blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet*, 2001; 35: 1033–41.
12. Hansson L, Lindholm LH, Ekborn T et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. *Lancet*, 1999; 34: 1129–33.
13. Dahlof B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. *Lancet*, 2002, 359: 995–1003.

Capítulo 6 – Tratamento Medicamentoso

1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. *JAMA*, 1996; 273: 1571–6.
2. Padwal R, Straus SE, McAlister FA. Cardiovascular risk factors and their impact on decision to treat hypertension: an evidence-based review. *BMJ*, 2001; 322: 977–80.
3. Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. *JAMA* 1977; 277: 739–45.
4. Wright JM, Lee C-H, Chamber GK. Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug. *CMAJ*, 1999; 161: 25–32.
5. SHEP-Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA*, 1991; 265: 3255–64.
6. Medical Research Council Working Party. MRC trial of treatment of hypertension: principal results. *BMJ*, 1985; 291: 97–104.
7. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. *UKPDS* 39. *BMJ*, 1998; 317: 713–20.
8. Blood Pressure Lowering Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. *Lancet*, 2000; 356: 1955–64.
14. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. *Lancet*, 2002; 359: 1004–10.
15. Stassen JÁ, Fagard R, Thijs L. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic hypertension in Europe (SYST-EUR). *Lancet*, 1997; 350: 757–64.
16. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). *Lancet*, 2000; 356: 366–72.
17. Hansson L, Hedner T, Lund-Johansen P et al. Randomized trial of effects of calcium antagonists compared with diuretics and alpha-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet*, 2000; 356: 359–65.
18. Sykowsky PA, D'Agostino RB, Belanger AJ, Kannel WB. Secular Trends in Long Term Sustained Hypertension, Long Term Treatment and Cardiovascular Morbidity. The Framingham Heart Study 1950 to 1990. *Circulation*, 1996; 93: 697–703.
19. 1999 World Health Organization – International Society of Hypertension Guidelines for Management of Hypertension. *J. Hypertens*, 1999; 17: 151–83.

20. UK Prospective Diabetes Study Group. Tight blood pressure control and the risk of macrovascular and microvascular complications in type diabetes. UKPDS 38. *BMJ*, 1998; 317: 703–13.
21. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. *Lancet*, 1998; 351: 1755–62.
22. Lewis EJ, Hunsicker LG, Clarke WR. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med*, 2001; 345: 851–60.
23. Brenner BM, Cooper ME, Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*, 2001; 345: 861–9.
24. Peterson JC, Adler S, Bukart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of Diet in Renal Disease Study (MDRD). *Ann Intern Med*, 1995; 123: 754–62.
25. Krumholz HM, Parent EM, Tu N et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. *Arch Intern Med*, 1997; 157(1): 99–104.
26. Du X, Cruickshank K, McNamee R et al. Case-Control of stroke and quality of hypertension control in north west England. *BMJ*, 1997; 341: 272–6.
27. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Reserach Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT). *JAMA*, 2000; 283: 1967–75.
28. Pahor M, Psaty BM, Alderman MH et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analyses of randomized controlled trials. *Lancet*, 2000; 356: 1949–54.
29. Fletcher MD, Yussuf S, Kober L et al for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. *Lancet*, 2000; 355: 1575–81.
30. Garg R, Yussuf S. Colaborative Group on ACE-inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. *JAMA*, 1995; 273: 1450–6.
31. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *N Engl J Med*, 1993; 329: 1456–562.
32. Gansevoort RT, Sluiter, WJ, Hemmelder MH et al. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. *Nephrol Dial Transplant*, 1995; 10: 1963–74.
33. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. *N Engl J Med*, 1996; 334: 939–45.
34. Giatra I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomized trials. *Ann Intern Med*, 1997; 127: 337–45.
35. Pitt B, Poole-Wilson PA, Segal R et al. on behalf of the ELITE II investigators. Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial- the Losartan Heart Failure Survival Study – ELITE II. *Lancet*, 2000; 355: 1582–7.
36. Cohn JN, Tognoni G on behalf of Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med*, 2001; 345: 167–75.
37. Busnello RG, Melchior R, Faccin C et al. Características associadas ao abandono do acompanhamento de pacientes hipertensos atendidos em um ambulatório de referência. *Arq Bras Cardiol*, 2001; 76: 349–51.
38. Schaub AF, Steiner A, Vetter W. Compliance to treatment. *Clin and Exper Hypertension*, 1993; 15: 1121–30.
39. Horwitz RI, Horwitz SM. Adherence to the treatment and health outcomes. *Arch Intern Med*, 1993; 153: 1863–8.
40. Hasford J. Compliance and the benefit/risk relationship of antihypertensive treatment. *J Card Pharmacol*, 1992; 20(suppl 6): S30–S34.
41. Sherbourne CD, Hays RD, Ordway L et al. Antecedents of adherence to medical recommendations: results from the medical outcomes study. *J Behav Med*, 1992; 15: 447–68.
42. Pierin, A.M.G, Mion Jr D, Fukushima J, Pinto AR, Kaminaga M. O perfil de um grupo de pessoas hipertensas de acordo com conhecimento e gravidade da doença. In: *Rev Esc Enf USP*, 2001; 35: 11–8.
43. Lessa I, Fonseca J. Raça, aderência ao tratamento e/ou consultas e controle da hipertensão arterial. *Arq Bras Cardiol*, 1997; 68: 443–9.
44. DiMatteo RM, Sherbourne CD, Hays RD > Physicians characteristics influence patients' adherence to medical treatment: results from the medical outcomes study. *Health Psychol*, 1993; 12: 93–102.
45. Lip GYH, Beevers DG. Doctors, nurses, pharmacists and patients – the Racional Evaluation and choice in Hypertension (REACH) Survey of Hypertension Care Delivery. *Blood Pressure*, 1997; 6: 6–10.
46. Pierin AMG. Adesão ao tratamento conceitos. In: Nobre F, Pierin A, Mion Jr D. Adesão ao tratamento: o grande desafio da hipertensão. São Paulo: Lemos Editorial, 2001; 21–33.

Capítulo 7 – Situações Especiais

1. Diez Roux AV, Merkin SS, Arnett D, Chambless L, Massing M, Nieto J, Sorlie P, Szklo M, Tyroler HA, Watson RL. Neighborhood of residence and incidence of coronary heart disease. *N Engl J Med*, 2001; 345: 99–106.
2. Benetos A, Safar M, Smulyan H, Richard JL, Ducimetière P, Guize L. Pulse pressure. A predictor of long-term cardiovascular mortality in a French male population. *Hypertension*, 1997; 30: 1410–5.
3. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? *The Framingham Heart Study*. *Circulation*, 1999; 100: 354–60.
4. Syst-Eur Trial Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. *Lancet*, 1997; 350: 757–64.
5. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. *JAMA*, 1991; 265: 3255–64.
6. Hansson L, Lindholm LH, Ekblom T, Dahlöf B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U. STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet*, 2000; 354: 1751–6.
7. Update on the 1987 Task Force Report on high blood pressure in children and adolescents. A working group report from National high blood pressure education program. *Pediatrics*, 1996; 98: 649–58.
8. Osório-Wender MC, Vitola D, Spritzer PM. Percutaneous 17beta-estradiol replacement therapy in hypertensive postmenopausal women. *Braz J Med Biol Res*, 1998; 30: 1047–53.
9. Atallah AN, Mesquita MRS, Duarte ML, Fernandes MCA, Sustovich DR, Gebara M, Camano L, Grisso JÁ. “Estudo Prospectivo Cohort de Grávidas Crônicas: Complicações Maternas e Fetais”. *J Bras Nefrol*, 1990; 12(3): 113–20.
10. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. *Am J Obstet Gynecol*, 2000; 183: S1–S22.
11. Briggs GG, Freeman RK, Yaffe SJ. *Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk*. 5th ed. Baltimore (MD): Williams and Wilkins, 1998.
12. UK Prospective Diabetes Study Group. Tight blood pressure control and the risk of macrovascular and microvascular complications in type diabetes. UKPDS 38. *BMJ*, 1998; 317: 703–13.
13. Parving HH, Anderson AR, Smidit UM, Anderson AA, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. *Lancet*, 1983; 1: 1175–8, (A).
14. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting – enzyme inhibitor, Ramipril on cardiovascular events in high risk patients. *N Engl J Med*, 2000; 342: 145–53 (A).
15. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet*, 2000; 355: 253–9 (A).
16. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. *N Engl J Med*, 2000; 342: 905–12.
17. Hansson L, Lindholm LH, Niskanen L. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. *Lancet*, 1999; 353: 611–6, (A).
18. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. *N Engl J Med*, 1993; 329: 1456–62, (A).
19. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbersartan on the development of diabetic nephropathy in patients with Type 2 diabetes. *N Engl J Med*, 2001; 345: 870–8 (A).
20. Lewis EJ, Hunsicker LG, Clarke WR. Renoprotective effect of the angiotensin receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes. *N Eng J Med*, 2001; 345: 851–60, (A).
21. Brenner BM, Cooper ME, Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*, 2001; 345: 861–9.
22. McAlister FA, Levine M, Zarnke KB et al. The 2000 Canadian recommendations for the management of hypertension: Part one – therapy. *Can J Cardiol*, 2001; 17: 543–59.
23. Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *Lancet*, 2001; 358: 1033–41.
24. Van Gijn J. The PROGRESS Trial: Preventing strokes by lowering blood pressure in patients with cerebral ischaemia. *Emerging Therapies: Critique of an Important Advance*. *Stroke*, 2002; 33: 319–20.
25. Powers WJ. Acute hypertension after stroke: the scientific basis for treatment decisions. *Neurology*, 1993; 43: 461–7.
26. Morfis L, Schwartz RS, Poulos R et al. Blood pressure changes in acute cerebral infarction and hemorrhage. *Stroke*, 1997; 28: 1401–5.

27. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. *BMJ*, 1998; 316(7141): 1337–43.
28. Sleight P. Angiotensin II and trials of cardiovascular outcomes. *Am J Cardiol*, 2002; 89(2A): 11A–16A.
29. Gibson RS, Hansen JF, Messerli F, Schechtman KB, Boden WE. Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second danish verapamil infarction trial studies. *Am J Cardiol*, 2000; 86(3): 275–9.
30. Cohn JN, Ziesche S, Smith R, Anad I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Effect of calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. *Circulation*, 1997; 96: 856–63.
31. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. *N Engl J Med*, 1996; 334: 1349–55.
32. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J. MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). *JAMA*, 2000; 283: 1295–302.
33. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality with severe heart failure. *N Engl J Med*, 1999; 341: 709–17.
34. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. *Circulation*, 1998; 97(1): 48–54.
35. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med*, 2000; 342: 1378–84.
36. Nieto FJ, Young TB, Lind BK et al. Association of sleep-disordered breathing sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. *JAMA*, 2000; 283: 1829–36.
37. Davies CWH, Crosby JH, Mullins RL, Barbour C, Davies RJO, Stradling JR. Case-control study of 24 hour ambulatory blood pressure in patients with obstructive.
 1. Claybutin EB, Di Pette. DJ. Hypertension induced by drugs and other substances. *Semin Nephrol*, 1995; 15: 72–86.
 2. Caetano ER, Zatz R, Saldanha LB, Praxedes JN. Hypertensive nephrosclerosis as a relevant cause of chronic renal failure. *Hypertension*, 2001; 38: 171–6.
 3. Klag MJ, Whelton PK, Randall BL et al. Blood Pressure and End-Stage Renal Disease in Men. *N Eng J Med*, 1996; 334: 13–8.
 4. Klahr S, Levey AS, Beck GJ et al. Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. *N Engl J Med*, 1994; 330: 877–84.
 5. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). *Lancet*, 1997; 349: 1857.
 6. Brenner BM, Cooper ME, Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med*, 2001; 345: 861–9.
 7. Lewis EJ, Hunsicker LG, Clarke WR et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbersatan in patients with nephropathy due to type 2 diabetes. *N Eng J Med*, 2001; 345: 851–60.
 8. Bakris GL, Copley JB, Vicknais N et al. Calcium-channel blockers versus other anti-hypertensive therapies on progression NIDDM associated nephropathy. *Kidney Int*, 1996; 50: 1641–50.
 9. De Lima JJ, Vieira ML, Abensur H, Krieger EM. Baseline blood pressure and other variables influencing survival on hemodialysis of patients without overt cardiovascular disease. *Nephrol Dial Transplant*, 2001; 16(4): 793–7 - B.
 10. Port FK, Hulbert-Shearon TE, Wolfe RA et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. *AmJ Kidney Dis*, 1999; 33: 507–17 - A.
 11. Fagugli RM, Reboldi G, Quintaliani G et al. Short daily hemodialysis: Blood pressure control and left ventricular mass reduction in Hypertensive hemodialysis patients. *Am J Kidney Diseases*, 2001; 38(2): 371–6 - B.
 12. Fernandez-Fresnedo G, Palomar R, Escallada R et al. Hypertension and long-term renal allograft survival: effect of early glomerular filtration rate. *Nephrol Dial Transplant*, 2001; 16(Suppl 1): 105–9 - B.
 13. Hernandez D, Lacalzada J, Salido et al. Regression of left ventricular hypertrophy by lisinopril after renal transplation: role of ACE gene polymorphism. *Kidney Int*, 2000; 58(2): 889–97 - B.
 14. Venkat-Raman G, Feehally J, Elliott HL et al. Renal and haemodynamic effects of amlodipine and nifedipine in hypertensive renal transplant recipients. *Nephrol Dial Transplant*, 1998; 13(10): 2612–6 - C.

15. Mann S, Pickering TG. Detection of renovascular hypertension. *Ann Intern Med*, 1992; 117: 845–53.
16. Kaplan MN. Screening for renovascular hypertension *UpToDate*, vol 9, no 1, 2001.
17. Minram A. Renal effects of antihypertensive agents in parenchymal renal disease and renovascular hypertension. *J Cardiovasc Pharmacol* 1992; 19(Suppl 6): S45–S50 – D.
18. Novick AC, Pohl MA, Schreiber M et al. Renovascularization for preservation of renal function in patients with atherosclerotic renovascular disease. *Urol Clin North Am*, 1984; 11: 477–87 – C.
19. Oskin TC, Hansen KJ, Ditch JS et al. Chronic renal artery occlusion : nephrectomy versus revascularization. *J Vasc Surg*, 1999; 29: 140–9 – C.
20. Ramsay LE, Walter PC. Blood pressure response to percutaneous transluminal angioplasty for renovascular hypertension: an overview of published series. *Br Med J*, 1990; 300: 569–72.
21. Blum U, Krumme B, Flugel P et al. Treatment of ostial renal artery stenosis with vascular endoprosthesis after unsuccessful balloon angioplasty. *N Engl J Med*, 1997; 336: 459–65 – C.
22. Pacak K, Linehan WM, Eisenhofer G et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. *Ann Intern Med*, 2001; 315–29.
23. Goldstein RE, O'Neill JA Jr, Holcomb GW III et al. Clinical experience over 48 years with pheochromocytoma. *Ann Surg*, 1999; 229(6): 755–64.
24. Maurea S, Cuocolo A, Reynolds JC, Tumei SS et al. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. *J Nucl Med*, 1993; 34: 173–9.
25. Ulchaker JC, Goldfarb DA, Bravo EL, Novick AC. Successful outcomes in pheochromocytoma surgery in the modern era. *J Urol*, 1999; 161: 764–7.
26. Young WF Jr. Pheochromocytoma: issues in diagnosis & treatment. *Comprehensive Therapy*, 1997; 23: 319–26.
27. Ganguly A. Primary aldosteronism. *N Engl J Med*, 1998; 339: 1828–34.
28. Young WF Jr. Primary aldosteronism: a common and curable form of hypertension. *Cardiology in review*, 1999; 7: 2107–14.
29. Foo R, O'Shaughnessy, Brown MJ. Hyperaldosteronism: recent concepts, diagnosis and management. *Postgrad Med J*, 2001; 77: 639–44.
30. Saito I, Kunihiro I, Saruta T. Hypothyroidism as a cause of hypertension. *Hypertension*, 1983; 5: 112.
31. Levey GS. Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. *Am J Med*, 1990; 88: 6.
32. Sangal AK, Beevers DG. Parathyroid hypertension. *Br Med J*, 1983; 286: 498–499. Editorial.
33. Ezzat S, Forster MJ, Harris AG. Acromegaly: Clinical and biochemical features in 500 patients. *Medicine*, 1994; 73: 233–40.
34. Sudhir K, Jennings GL, Elser MD et al. Hydrocortisone-induced hypertension human: pressor responsiveness and sympathetic function. *Hypertension*, 1989; 13: 416.

Capítulo 9 – Prevenção da Hipertensão e dos Fatores de Risco Associados

1. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med*, 2001; 345: 1291–7.
2. The trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention. Phase I. *JAMA*; 1992; 267: 1213–20.
3. American College of Sports Medicine. ACSM's Guidelines for exercise testing and prescription. Baltimore: Williams & Wilkins, 2000.
4. Sacks FM, Svetkey LP, Vollmer WM et al. DASH – Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. *N Engl J Med*, 2001; 344: 3–10.
5. III Diretrizes Brasileiras sobre Dislipidemias e Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. *Arq Bras Cardiol*, 2001; 77(supl III): 1–48.
6. American Diabetes Association. Standards of Medical Care for patients with diabetes mellitus. *Diabetes Care*, 2002; 25(Suppl 1): S33–S49.

Produção Gráfica e Editorial - BG Cultural

Rua Ministro Nelson Hungria, 239 - Sala 5 - 05690-050 - São Paulo - SP - Telefax: (11) 3758-1787 / 3758-2197. E-mail: bg@uol.com.br

Médico / Jornalista Responsável: Benemar Guimarães - CRMSP 11243 / MTb 8668.

Assessoria Editorial: Marco Barbato, Eliane R. Palumbo. Revisão: Márcio Barbosa. Coordenadoria de Atendimento: Mabel Rigon.